Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Operating Leases: 2022-2025

Historic Operating Leases for Cellebrite DI (CLBT) over the last 2 years, with Sep 2025 value amounting to -$2.6 million.

  • Cellebrite DI's Operating Leases rose 26.90% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year increase of 26.90%. This contributed to the annual value of $11.0 million for FY2024, which is 19.79% up from last year.
  • As of Q3 2025, Cellebrite DI's Operating Leases stood at -$2.6 million, which was down 120.78% from -$1.2 million recorded in Q1 2025.
  • Over the past 5 years, Cellebrite DI's Operating Leases peaked at $11.0 million during Q4 2024, and registered a low of -$4.5 million during Q3 2023.
  • Over the past 3 years, Cellebrite DI's median Operating Leases value was -$2.1 million (recorded in 2023), while the average stood at -$7,800.
  • Its Operating Leases has fluctuated over the past 5 years, first decreased by 11.55% in 2023, then increased by 26.90% in 2025.
  • Over the past 4 years, Cellebrite DI's Operating Leases (Quarterly) stood at $10.4 million in 2022, then declined by 11.55% to $9.2 million in 2023, then climbed by 19.79% to $11.0 million in 2024, then rose by 26.90% to -$2.6 million in 2025.
  • Its Operating Leases stands at -$2.6 million for Q3 2025, versus -$1.2 million for Q1 2025 and $11.0 million for Q4 2024.